Aurora Kinase Inhibitors: Which Role in the Treatment of Chronic Myelogenous Leukemia Patients Resistant to Imatinib?
Abstract
Share and Cite
Martinelli, G.; Papayannidis, C.; Iacobucci, I.; Soverini, S.; Cilloni, D.; Baccarani, M. Aurora Kinase Inhibitors: Which Role in the Treatment of Chronic Myelogenous Leukemia Patients Resistant to Imatinib? Hematol. Rev. 2009, 1, e1. https://doi.org/10.4081/hr.2009.e1
Martinelli G, Papayannidis C, Iacobucci I, Soverini S, Cilloni D, Baccarani M. Aurora Kinase Inhibitors: Which Role in the Treatment of Chronic Myelogenous Leukemia Patients Resistant to Imatinib? Hematology Reviews. 2009; 1(1):e1. https://doi.org/10.4081/hr.2009.e1
Chicago/Turabian StyleMartinelli, Giovanni, Cristina Papayannidis, Ilaria Iacobucci, Simona Soverini, Daniela Cilloni, and Michele Baccarani. 2009. "Aurora Kinase Inhibitors: Which Role in the Treatment of Chronic Myelogenous Leukemia Patients Resistant to Imatinib?" Hematology Reviews 1, no. 1: e1. https://doi.org/10.4081/hr.2009.e1